Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (12): 1378-1390.doi: 10.12092/j.issn.1009-2501.2023.12.008

Previous Articles     Next Articles

Research progress on the treatment of Alzheimer's disease based on the target of mammalian target of rapamycin

WANG Zhun1,2, SUN Yuying1,2, HUANG Hanchang1,2   

  1. 1Institute of Functional Factors and Brain Sciences, Beijing Union University, Beijing 100023, China; 2Key Laboratory of Natural Products Development and Innovative Drug Research, Beijing Union University, Beijing 100023, China
  • Received:2023-04-26 Revised:2023-07-27 Online:2023-12-26 Published:2023-12-21

Abstract:

Mammalian target of rapamycin (mTOR) regulates cell survival, proliferation, and metabolism. Alzheimer's disease (AD) is a common neurodegenerative disease with a complex pathogenesis and is closely related to aging. Studies have found that the pathological development of AD is often accompanied by changes in mTOR activity, but the role of mTOR in the pathogenesis of AD is not clear. In this paper, the complex of mTOR and its signaling pathways are first introduced, focusing on the effects of mTOR signaling pathways on synaptic plasticity and memory function, autophagy, β-amyloid-β (Aβ), Tau protein and brain insulin resistance and other AD pathological features, secondly, the regulatory effects of mTOR signaling pathways in anti-aging and life prolongation are described, and finally the application of mTOR inhibitors in AD pathological research is introduced to provide new ideas for delaying and improving AD.

Key words: mammalian target of rapamycin, Alzheimer's disease, autophagy, aging, mTOR inhibitors

CLC Number: